PATENT CLAIM ANALYSIS

Application Number: 15756483
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "002400"]

Abstract:
Disclosed are synthetic peptides and peptide compositions, including peptide conjugates, that can ameliorate and/or block the cytotoxicity of  C. difficile  TcdB toxin, and methods of their use for inhibiting the activity of TcdB and protecting against damage during  C. difficile  disease, and/or for use as cell penetrating peptides for enhancing the delivery of particular heterogenous molecules into cells.

Claim (Index 20):
A method of treating a  Clostridium difficile  infection in a subject in need of such treatment, comprising:\n administering to the subject an effective amount of a pharmaceutical composition comprising at least one of: (1) a peptide disposed in a pharmaceutically-acceptable carrier or vehicle, the peptide comprising an amino acid sequence X 1  X 2  X 3  X 4  X 5  X 6  X 7  X 8  X 9  X 10  X 11  (SEQ ID NO:67), wherein\n each of X 1 , X 2 , X 3 , X 4 , X 7 , X 8 , X 9 , X 10 , and X 11  is independently selected from the group consisting of gly, L-ala, L-arg, L-asn, L-asp, L-cys, L-glu, L-gln, L-his, L-ile, L-leu, L-lys, L-met, L-phe, L-pro, L-ser, L-thr, L-trp, L-tyr, L-val, D-ala, D-arg, D-asn, D-asp, D-cys, D-glu, D-gln, D-his, D-ile, D-leu, D-lys, D-met, D-phe, D-pro, D-ser, D-thr, D-trp, D-tyr, and D-val; \n X 5  is selected from gly, L-ala, L-ser, D-ala, and D-ser; \n X 6  is selected from L-asn, L-asp, L-gln, L-his, L-ser, L-thr, D-asn, D-asp, D-gln, D-his, D-ser, and D-thr; and \n wherein the amino acid sequence SEQ ID NO:67 has at least 63% identity with SEQ ID NO:1, has a length of from 15 to 100 amino acids, and has anti-TcdB activity and/or has cell penetrating activity; and (2) a peptide disposed in a pharmaceutically-acceptable carrier or vehicle, the peptide comprising an amino acid sequence:\n X 1  X 2  X 3  X 4  X 5  X 6  X 7  X 8  X 9  X 10  X 11  X 12  X 13  X 14  X 15  X 16  X 17  X 18  X 19  (SEQ ID NO:68), wherein \n each of X 1 , X 2 , X 3 , X 4 , X 7 , X 8 , X 9 , X 10 , X 11  X 12 , X 13  X 14  X 15  X 16  X 17  X 18  and X 19  is independently selected from the group consisting of gly, L-ala, L-arg, L-asn, L-asp, L-cys, L-glu, L-gln, L-his, L-ile, L-leu, L-lys, L-met, L-phe, L-pro, L-ser, L-Thr, L-trp, L-tyr, L-val, D-ala, D-arg, D-asn, D-asp, D-cys, D-glu, D-gln, D-his, D-ile, D-leu, D-lys, D-met, D-phe, D-pro, D-ser, D-thr, D-trp, D-tyr, and D-val; \n X 5  is selected from gly, L-ala, and D-ala; and \n X 6  is selected from L-asn, L-gln, L-his, D-asn, D-gln, and D-his; and \n wherein the peptide has at least 73% identity with SEQ ID NO:6, and has inhibitory activity against TcdB toxins and/or cell penetrating activity.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 88.0
- Lexical Diversity: 1.43182
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['10196394', '13262186', '15119058', '14005135', '10202915']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7936192659145612
- 35 USC 102 Novelty (BERT): 0.5339791790628409
- Combined Prediction Score: 0.7676552572293892
- Mean Citation Score: 370.798698
- Max Citation Score: 375.74005
- Similarity Product: 248.28099987156983

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test